#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Academic editor : Alejandro Sosnik
1-1	0-8	Academic	person[1]	new[1]	appos	1-4[2_1]
1-2	9-15	editor	person[1]	new[1]	_	_
1-3	16-17	:	_	_	_	_
1-4	18-27	Alejandro	person[2]	giv[2]	_	_
1-5	28-34	Sosnik	person[2]	giv[2]	_	_

#Text=1 .
2-1	35-36	1	quantity	new	_	_
2-2	37-38	.	_	_	_	_

#Text=Introduction
3-1	39-51	Introduction	abstract	new	_	_

#Text=Drug-delivery systems are difficult to design as there exist various mechanisms that are involved in the release processes of drug .
4-1	52-65	Drug-delivery	abstract[5]	new[5]	coref	6-28[0_5]
4-2	66-73	systems	abstract[5]	new[5]	_	_
4-3	74-77	are	_	_	_	_
4-4	78-87	difficult	_	_	_	_
4-5	88-90	to	_	_	_	_
4-6	91-97	design	abstract	new	coref|none	26-3[190_0]|4-6[0_190]
4-7	98-100	as	_	_	_	_
4-8	101-106	there	_	_	_	_
4-9	107-112	exist	_	_	_	_
4-10	113-120	various	abstract[6]	new[6]	_	_
4-11	121-131	mechanisms	abstract[6]	new[6]	_	_
4-12	132-136	that	_	_	_	_
4-13	137-140	are	_	_	_	_
4-14	141-149	involved	_	_	_	_
4-15	150-152	in	_	_	_	_
4-16	153-156	the	event[8]	new[8]	_	_
4-17	157-164	release	event|event[8]	new|new[8]	_	_
4-18	165-174	processes	event[8]	new[8]	_	_
4-19	175-177	of	event[8]	new[8]	_	_
4-20	178-182	drug	event[8]|substance	new[8]|new	coref	5-8
4-21	183-184	.	_	_	_	_

#Text=Various factors need to be considered for drug delivery , such as the degree of absorption or the diffusion limitations of the drug in the medium .
5-1	185-192	Various	abstract[10]	new[10]	coref	16-6[106_10]
5-2	193-200	factors	abstract[10]	new[10]	_	_
5-3	201-205	need	_	_	_	_
5-4	206-208	to	_	_	_	_
5-5	209-211	be	_	_	_	_
5-6	212-222	considered	_	_	_	_
5-7	223-226	for	_	_	_	_
5-8	227-231	drug	substance|abstract[12]	giv|new[12]	coref|coref|coref|coref	5-22[17_0]|6-12[24_12]|5-22[17_0]|6-12[24_12]
5-9	232-240	delivery	abstract[12]	new[12]	_	_
5-10	241-242	,	abstract[12]	new[12]	_	_
5-11	243-247	such	abstract[12]	new[12]	_	_
5-12	248-250	as	abstract[12]	new[12]	_	_
5-13	251-254	the	abstract[12]|abstract[13]	new[12]|new[13]	_	_
5-14	255-261	degree	abstract[12]|abstract[13]	new[12]|new[13]	_	_
5-15	262-264	of	abstract[12]|abstract[13]	new[12]|new[13]	_	_
5-16	265-275	absorption	abstract[12]|abstract[13]|abstract	new[12]|new[13]|new	_	_
5-17	276-278	or	abstract[12]|abstract[13]	new[12]|new[13]	_	_
5-18	279-282	the	abstract[12]|abstract[13]|abstract[16]	new[12]|new[13]|new[16]	_	_
5-19	283-292	diffusion	abstract[12]|abstract[13]|abstract|abstract[16]	new[12]|new[13]|new|new[16]	coref	16-2
5-20	293-304	limitations	abstract[12]|abstract[13]|abstract[16]	new[12]|new[13]|new[16]	_	_
5-21	305-307	of	abstract[12]|abstract[13]|abstract[16]	new[12]|new[13]|new[16]	_	_
5-22	308-311	the	abstract[12]|abstract[13]|abstract[16]|substance[17]	new[12]|new[13]|new[16]|giv[17]	coref	6-12[0_17]
5-23	312-316	drug	abstract[12]|abstract[13]|abstract[16]|substance[17]	new[12]|new[13]|new[16]|giv[17]	_	_
5-24	317-319	in	abstract[12]|abstract[13]|abstract[16]|substance[17]	new[12]|new[13]|new[16]|giv[17]	_	_
5-25	320-323	the	abstract[12]|abstract[13]|abstract[16]|substance[17]|place[18]	new[12]|new[13]|new[16]|giv[17]|new[18]	_	_
5-26	324-330	medium	abstract[12]|abstract[13]|abstract[16]|substance[17]|place[18]	new[12]|new[13]|new[16]|giv[17]|new[18]	_	_
5-27	331-332	.	_	_	_	_

#Text=In recent years , the use of porous silica materials in drug delivery has attracted a lot of interest due to its potential for the development of systems that are site-specific and that offer time-dependent controlled delivery .
6-1	333-335	In	_	_	_	_
6-2	336-342	recent	time[19]	new[19]	_	_
6-3	343-348	years	time[19]	new[19]	_	_
6-4	349-350	,	_	_	_	_
6-5	351-354	the	abstract[20]	new[20]	_	_
6-6	355-358	use	abstract[20]	new[20]	_	_
6-7	359-361	of	abstract[20]	new[20]	_	_
6-8	362-368	porous	abstract[20]|substance[22]	new[20]|new[22]	ana	7-4[0_22]
6-9	369-375	silica	abstract[20]|organization|substance[22]	new[20]|new|new[22]	coref	7-8
6-10	376-385	materials	abstract[20]|substance[22]	new[20]|new[22]	_	_
6-11	386-388	in	abstract[20]|substance[22]	new[20]|new[22]	_	_
6-12	389-393	drug	abstract[20]|substance[22]|substance|abstract[24]	new[20]|new[22]|giv|giv[24]	ana|coref|ana|coref	6-22[0_24]|8-45|6-22[0_24]|8-45
6-13	394-402	delivery	abstract[20]|substance[22]|abstract[24]	new[20]|new[22]|giv[24]	_	_
6-14	403-406	has	_	_	_	_
6-15	407-416	attracted	_	_	_	_
6-16	417-418	a	_	_	_	_
6-17	419-422	lot	_	_	_	_
6-18	423-425	of	_	_	_	_
6-19	426-434	interest	_	_	_	_
6-20	435-438	due	_	_	_	_
6-21	439-441	to	_	_	_	_
6-22	442-445	its	abstract|abstract[26]	giv|new[26]	coref|coref	6-35[29_0]|6-35[29_0]
6-23	446-455	potential	abstract[26]	new[26]	_	_
6-24	456-459	for	abstract[26]	new[26]	_	_
6-25	460-463	the	abstract[26]|event[27]	new[26]|new[27]	_	_
6-26	464-475	development	abstract[26]|event[27]	new[26]|new[27]	_	_
6-27	476-478	of	abstract[26]|event[27]	new[26]|new[27]	_	_
6-28	479-486	systems	abstract[26]|event[27]|abstract	new[26]|new[27]|giv	_	_
6-29	487-491	that	_	_	_	_
6-30	492-495	are	_	_	_	_
6-31	496-509	site-specific	_	_	_	_
6-32	510-513	and	_	_	_	_
6-33	514-518	that	_	_	_	_
6-34	519-524	offer	_	_	_	_
6-35	525-539	time-dependent	abstract[29]	giv[29]	_	_
6-36	540-550	controlled	abstract[29]	giv[29]	_	_
6-37	551-559	delivery	abstract[29]	giv[29]	_	_
6-38	560-561	.	_	_	_	_

#Text=Given in particular their non-toxic properties , silica aerogels are a special kind of porous silica materials consisting of highly mesoporous nanostructures .
7-1	562-567	Given	_	_	_	_
7-2	568-570	in	_	_	_	_
7-3	571-581	particular	abstract[31]	new[31]	coref	8-8[40_31]
7-4	582-587	their	substance|abstract[31]	giv|new[31]	coref	7-13[35_0]
7-5	588-597	non-toxic	abstract[31]	new[31]	_	_
7-6	598-608	properties	abstract[31]	new[31]	_	_
7-7	609-610	,	_	_	_	_
7-8	611-617	silica	organization|substance[33]	giv|new[33]	coref|coref|coref|coref	7-16|8-5[39_33]|7-16|8-5[39_33]
7-9	618-626	aerogels	substance[33]	new[33]	_	_
7-10	627-630	are	_	_	_	_
7-11	631-632	a	_	_	_	_
7-12	633-640	special	_	_	_	_
7-13	641-645	kind	substance[35]	giv[35]	_	_
7-14	646-648	of	substance[35]	giv[35]	_	_
7-15	649-655	porous	substance[35]	giv[35]	_	_
7-16	656-662	silica	organization|substance[35]	giv|giv[35]	coref	9-4
7-17	663-672	materials	substance[35]	giv[35]	_	_
7-18	673-683	consisting	_	_	_	_
7-19	684-686	of	_	_	_	_
7-20	687-693	highly	object[37]	new[37]	_	_
7-21	694-704	mesoporous	person|object[37]	new|new[37]	_	_
7-22	705-719	nanostructures	object[37]	new[37]	_	_
7-23	720-721	.	_	_	_	_

#Text=The porous structure make the aerogels have many special properties , such as low density ( 1000 kg/m3 to about 1 kg/m3 ) , high porosity ( ~99 % ) and inner surface area ( 1000 m2/g ) , which is necessary for efficient drug loading .
8-1	722-725	The	abstract[38]	new[38]	_	_
8-2	726-732	porous	abstract[38]	new[38]	_	_
8-3	733-742	structure	abstract[38]	new[38]	_	_
8-4	743-747	make	_	_	_	_
8-5	748-751	the	substance[39]	giv[39]	coref	9-4[52_39]
8-6	752-760	aerogels	substance[39]	giv[39]	_	_
8-7	761-765	have	_	_	_	_
8-8	766-770	many	abstract[40]	giv[40]	_	_
8-9	771-778	special	abstract[40]	giv[40]	_	_
8-10	779-789	properties	abstract[40]	giv[40]	_	_
8-11	790-791	,	abstract[40]	giv[40]	_	_
8-12	792-796	such	abstract[40]	giv[40]	_	_
8-13	797-799	as	abstract[40]	giv[40]	_	_
8-14	800-803	low	abstract[40]|abstract[41]	giv[40]|new[41]	_	_
8-15	804-811	density	abstract[40]|abstract[41]	giv[40]|new[41]	_	_
8-16	812-813	(	abstract[40]	giv[40]	_	_
8-17	814-818	1000	abstract[40]|quantity[42]	giv[40]|new[42]	_	_
8-18	819-824	kg/m3	abstract[40]|quantity[42]	giv[40]|new[42]	_	_
8-19	825-827	to	abstract[40]|quantity[42]	giv[40]|new[42]	_	_
8-20	828-833	about	abstract[40]|quantity[42]|quantity[43]	giv[40]|new[42]|new[43]	_	_
8-21	834-835	1	abstract[40]|quantity[42]|quantity[43]	giv[40]|new[42]|new[43]	_	_
8-22	836-841	kg/m3	abstract[40]|quantity[42]|quantity[43]	giv[40]|new[42]|new[43]	_	_
8-23	842-843	)	abstract[40]	giv[40]	_	_
8-24	844-845	,	abstract[40]	giv[40]	_	_
8-25	846-850	high	abstract[40]|abstract[44]	giv[40]|new[44]	_	_
8-26	851-859	porosity	abstract[40]|abstract[44]	giv[40]|new[44]	_	_
8-27	860-861	(	abstract[40]	giv[40]	_	_
8-28	862-865	~99	abstract[40]|quantity[45]	giv[40]|new[45]	_	_
8-29	866-867	%	abstract[40]|quantity[45]	giv[40]|new[45]	_	_
8-30	868-869	)	abstract[40]	giv[40]	_	_
8-31	870-873	and	abstract[40]	giv[40]	_	_
8-32	874-879	inner	abstract[40]|abstract[47]	giv[40]|new[47]	ana	10-21[0_47]
8-33	880-887	surface	abstract[40]|place|abstract[47]	giv[40]|new|new[47]	coref	9-13
8-34	888-892	area	abstract[40]|abstract[47]	giv[40]|new[47]	_	_
8-35	893-894	(	_	_	_	_
8-36	895-899	1000	quantity[48]	new[48]	_	_
8-37	900-904	m2/g	quantity[48]	new[48]	_	_
8-38	905-906	)	_	_	_	_
8-39	907-908	,	_	_	_	_
8-40	909-914	which	_	_	_	_
8-41	915-917	is	_	_	_	_
8-42	918-927	necessary	_	_	_	_
8-43	928-931	for	_	_	_	_
8-44	932-941	efficient	quantity[50]	new[50]	coref	18-9[0_50]
8-45	942-946	drug	substance|quantity[50]	giv|new[50]	coref	9-19[56_0]
8-46	947-954	loading	quantity[50]	new[50]	_	_
8-47	955-956	.	_	_	_	_

#Text=In addition , silica aerogels can be grafted with various groups by surface modification , which could deliver the drug to targeted regions .
9-1	957-959	In	_	_	_	_
9-2	960-968	addition	_	_	_	_
9-3	969-970	,	_	_	_	_
9-4	971-977	silica	organization|substance[52]	giv|giv[52]	coref|coref|coref|coref	12-5|13-5[0_52]|12-5|13-5[0_52]
9-5	978-986	aerogels	substance[52]	giv[52]	_	_
9-6	987-990	can	_	_	_	_
9-7	991-993	be	_	_	_	_
9-8	994-1001	grafted	_	_	_	_
9-9	1002-1006	with	_	_	_	_
9-10	1007-1014	various	person[53]	new[53]	_	_
9-11	1015-1021	groups	person[53]	new[53]	_	_
9-12	1022-1024	by	person[53]	new[53]	_	_
9-13	1025-1032	surface	person[53]|place|abstract[55]	new[53]|giv|new[55]	_	_
9-14	1033-1045	modification	person[53]|abstract[55]	new[53]|new[55]	_	_
9-15	1046-1047	,	_	_	_	_
9-16	1048-1053	which	_	_	_	_
9-17	1054-1059	could	_	_	_	_
9-18	1060-1067	deliver	_	_	_	_
9-19	1068-1071	the	substance[56]	giv[56]	coref	13-18[87_56]
9-20	1072-1076	drug	substance[56]	giv[56]	_	_
9-21	1077-1079	to	substance[56]	giv[56]	_	_
9-22	1080-1088	targeted	substance[56]|place[57]	giv[56]|new[57]	_	_
9-23	1089-1096	regions	substance[56]|place[57]	giv[56]|new[57]	_	_
9-24	1097-1098	.	_	_	_	_

#Text=Trans-resveratrol ( RSV ) , whose full name is non-flavonoid phytoalexin trans-resveratrol , has many biological functions by virtue of its antibacterial , anti-inflammatory , anticancer , anti-thrombosis , anti-hyperlipidemia and anti-lipid peroxidation characteristics .
10-1	1099-1116	Trans-resveratrol	substance	new	coref	10-11[61_0]
10-2	1117-1118	(	_	_	_	_
10-3	1119-1122	RSV	abstract	new	coref	12-8
10-4	1123-1124	)	_	_	_	_
10-5	1125-1126	,	_	_	_	_
10-6	1127-1132	whose	abstract[60]	new[60]	_	_
10-7	1133-1137	full	abstract[60]	new[60]	_	_
10-8	1138-1142	name	abstract[60]	new[60]	_	_
10-9	1143-1145	is	_	_	_	_
10-10	1146-1159	non-flavonoid	_	_	_	_
10-11	1160-1171	phytoalexin	substance[61]	giv[61]	coref	30-7[0_61]
10-12	1172-1189	trans-resveratrol	substance[61]	giv[61]	_	_
10-13	1190-1191	,	_	_	_	_
10-14	1192-1195	has	_	_	_	_
10-15	1196-1200	many	abstract[62]	new[62]	coref	11-1[70_62]
10-16	1201-1211	biological	abstract[62]	new[62]	_	_
10-17	1212-1221	functions	abstract[62]	new[62]	_	_
10-18	1222-1224	by	_	_	_	_
10-19	1225-1231	virtue	abstract[63]	new[63]	_	_
10-20	1232-1234	of	abstract[63]	new[63]	_	_
10-21	1235-1238	its	abstract[63]|abstract|abstract[69]	new[63]|giv|new[69]	_	_
10-22	1239-1252	antibacterial	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-23	1253-1254	,	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-24	1255-1272	anti-inflammatory	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-25	1273-1274	,	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-26	1275-1285	anticancer	abstract[63]|abstract|abstract[69]	new[63]|new|new[69]	_	_
10-27	1286-1287	,	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-28	1288-1303	anti-thrombosis	abstract[63]|abstract|abstract[69]	new[63]|new|new[69]	_	_
10-29	1304-1305	,	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-30	1306-1325	anti-hyperlipidemia	abstract[63]|abstract|abstract[69]	new[63]|new|new[69]	_	_
10-31	1326-1329	and	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-32	1330-1340	anti-lipid	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-33	1341-1353	peroxidation	abstract[63]|event|abstract[69]	new[63]|new|new[69]	_	_
10-34	1354-1369	characteristics	abstract[63]|abstract[69]	new[63]|new[69]	_	_
10-35	1370-1371	.	_	_	_	_

#Text=These functions determined resveratrol has many supplementations in treatment of cancer , diabetes , skin disorders and so on .
11-1	1372-1377	These	abstract[70]	giv[70]	_	_
11-2	1378-1387	functions	abstract[70]	giv[70]	_	_
11-3	1388-1398	determined	_	_	_	_
11-4	1399-1410	resveratrol	substance	new	_	_
11-5	1411-1414	has	_	_	_	_
11-6	1415-1419	many	abstract[72]	new[72]	_	_
11-7	1420-1436	supplementations	abstract[72]	new[72]	_	_
11-8	1437-1439	in	abstract[72]	new[72]	_	_
11-9	1440-1449	treatment	abstract[72]|abstract[73]	new[72]|new[73]	_	_
11-10	1450-1452	of	abstract[72]|abstract[73]	new[72]|new[73]	_	_
11-11	1453-1459	cancer	abstract[72]|abstract[73]|abstract	new[72]|new[73]|new	_	_
11-12	1460-1461	,	abstract[72]|abstract[73]	new[72]|new[73]	_	_
11-13	1462-1470	diabetes	abstract[72]|abstract[73]|abstract	new[72]|new[73]|new	_	_
11-14	1471-1472	,	abstract[72]|abstract[73]	new[72]|new[73]	_	_
11-15	1473-1477	skin	abstract[72]|abstract[73]|object|abstract[77]	new[72]|new[73]|new|new[77]	_	_
11-16	1478-1487	disorders	abstract[72]|abstract[73]|abstract[77]	new[72]|new[73]|new[77]	_	_
11-17	1488-1491	and	_	_	_	_
11-18	1492-1494	so	_	_	_	_
11-19	1495-1497	on	_	_	_	_
11-20	1498-1499	.	_	_	_	_

#Text=In this paper , silica aerogel and RSV was chosen as a carrier and a model drug , respectively .
12-1	1500-1502	In	_	_	_	_
12-2	1503-1507	this	abstract[78]	new[78]	coref	22-2[149_78]
12-3	1508-1513	paper	abstract[78]	new[78]	_	_
12-4	1514-1515	,	_	_	_	_
12-5	1516-1522	silica	organization|substance[80]|substance[81]	giv|new[80]|new[81]	coref|coref|coref|coref|coref|coref|coref|coref|coref	22-6|22-5[151_80]|24-12[168_81]|22-6|22-5[151_80]|24-12[168_81]|22-6|22-5[151_80]|24-12[168_81]
12-6	1523-1530	aerogel	substance[80]|substance[81]	new[80]|new[81]	_	_
12-7	1531-1534	and	substance[81]	new[81]	_	_
12-8	1535-1538	RSV	substance[81]|abstract	new[81]|giv	coref	15-12[100_0]
12-9	1539-1542	was	_	_	_	_
12-10	1543-1549	chosen	_	_	_	_
12-11	1550-1552	as	_	_	_	_
12-12	1553-1554	a	_	_	_	_
12-13	1555-1562	carrier	_	_	_	_
12-14	1563-1566	and	_	_	_	_
12-15	1567-1568	a	_	_	_	_
12-16	1569-1574	model	_	_	_	_
12-17	1575-1579	drug	_	_	_	_
12-18	1580-1581	,	_	_	_	_
12-19	1582-1594	respectively	_	_	_	_
12-20	1595-1596	.	_	_	_	_

#Text=Drug-delivery vehicles based on aerogels can be prepared by different methods , such as the addition of the drug during the conventional sol – gel process or during the post treatment of the synthesized aerogels .
13-1	1597-1610	Drug-delivery	object[83]	new[83]	_	_
13-2	1611-1619	vehicles	object[83]	new[83]	_	_
13-3	1620-1625	based	_	_	_	_
13-4	1626-1628	on	_	_	_	_
13-5	1629-1637	aerogels	substance	giv	coref	13-33[93_0]
13-6	1638-1641	can	_	_	_	_
13-7	1642-1644	be	_	_	_	_
13-8	1645-1653	prepared	_	_	_	_
13-9	1654-1656	by	_	_	_	_
13-10	1657-1666	different	abstract[85]	new[85]	_	_
13-11	1667-1674	methods	abstract[85]	new[85]	_	_
13-12	1675-1676	,	abstract[85]	new[85]	_	_
13-13	1677-1681	such	abstract[85]	new[85]	_	_
13-14	1682-1684	as	abstract[85]	new[85]	_	_
13-15	1685-1688	the	abstract[85]|abstract[86]	new[85]|new[86]	_	_
13-16	1689-1697	addition	abstract[85]|abstract[86]	new[85]|new[86]	_	_
13-17	1698-1700	of	abstract[85]|abstract[86]	new[85]|new[86]	_	_
13-18	1701-1704	the	abstract[85]|abstract[86]|substance[87]	new[85]|new[86]|giv[87]	coref	14-3[95_87]
13-19	1705-1709	drug	abstract[85]|abstract[86]|substance[87]	new[85]|new[86]|giv[87]	_	_
13-20	1710-1716	during	abstract[85]|abstract[86]	new[85]|new[86]	_	_
13-21	1717-1720	the	abstract[85]|abstract[86]|substance[88]	new[85]|new[86]|new[88]	_	_
13-22	1721-1733	conventional	abstract[85]|abstract[86]|substance[88]	new[85]|new[86]|new[88]	_	_
13-23	1734-1737	sol	abstract[85]|abstract[86]|substance[88]	new[85]|new[86]|new[88]	_	_
13-24	1738-1739	–	_	_	_	_
13-25	1740-1743	gel	substance|abstract[90]	new|new[90]	coref|coref	14-6[96_90]|14-6[96_90]
13-26	1744-1751	process	abstract[90]	new[90]	_	_
13-27	1752-1754	or	_	_	_	_
13-28	1755-1761	during	_	_	_	_
13-29	1762-1765	the	event[92]	new[92]	_	_
13-30	1766-1770	post	abstract|event[92]	new|new[92]	_	_
13-31	1771-1780	treatment	event[92]	new[92]	_	_
13-32	1781-1783	of	event[92]	new[92]	_	_
13-33	1784-1787	the	event[92]|substance[93]	new[92]|giv[93]	_	_
13-34	1788-1799	synthesized	event[92]|substance[93]	new[92]|giv[93]	_	_
13-35	1800-1808	aerogels	event[92]|substance[93]	new[92]|giv[93]	_	_
13-36	1809-1810	.	_	_	_	_

#Text=We added the drug during the aging process in this work .
14-1	1811-1813	We	person	acc	ana	20-15
14-2	1814-1819	added	_	_	_	_
14-3	1820-1823	the	substance[95]	giv[95]	coref	15-17[101_95]
14-4	1824-1828	drug	substance[95]	giv[95]	_	_
14-5	1829-1835	during	_	_	_	_
14-6	1836-1839	the	abstract[96]	giv[96]	coref	20-10[134_96]
14-7	1840-1845	aging	abstract[96]	giv[96]	_	_
14-8	1846-1853	process	abstract[96]	giv[96]	_	_
14-9	1854-1856	in	abstract[96]	giv[96]	_	_
14-10	1857-1861	this	abstract[96]|abstract[97]	giv[96]|new[97]	coref	21-3[139_97]
14-11	1862-1866	work	abstract[96]|abstract[97]	giv[96]|new[97]	_	_
14-12	1867-1868	.	_	_	_	_

#Text=The alcogel was brought into contactwith an aging solution which contains the RSV , and then the drug diffused into the alcogel pores from the aging solution .
15-1	1869-1872	The	substance[98]	new[98]	coref	17-22[117_98]
15-2	1873-1880	alcogel	substance[98]	new[98]	_	_
15-3	1881-1884	was	_	_	_	_
15-4	1885-1892	brought	_	_	_	_
15-5	1893-1897	into	_	_	_	_
15-6	1898-1909	contactwith	_	_	_	_
15-7	1910-1912	an	substance[99]	new[99]	coref	15-25[103_99]
15-8	1913-1918	aging	substance[99]	new[99]	_	_
15-9	1919-1927	solution	substance[99]	new[99]	_	_
15-10	1928-1933	which	_	_	_	_
15-11	1934-1942	contains	_	_	_	_
15-12	1943-1946	the	abstract[100]	giv[100]	coref	23-13[158_100]
15-13	1947-1950	RSV	abstract[100]	giv[100]	_	_
15-14	1951-1952	,	_	_	_	_
15-15	1953-1956	and	_	_	_	_
15-16	1957-1961	then	_	_	_	_
15-17	1962-1965	the	substance[101]	giv[101]	coref	17-14[115_101]
15-18	1966-1970	drug	substance[101]	giv[101]	_	_
15-19	1971-1979	diffused	_	_	_	_
15-20	1980-1984	into	_	_	_	_
15-21	1985-1988	the	object[102]	new[102]	coref	16-17[0_102]
15-22	1989-1996	alcogel	object[102]	new[102]	_	_
15-23	1997-2002	pores	object[102]	new[102]	_	_
15-24	2003-2007	from	object[102]	new[102]	_	_
15-25	2008-2011	the	object[102]|substance[103]	new[102]|giv[103]	coref	16-24[111_103]
15-26	2012-2017	aging	object[102]|substance[103]	new[102]|giv[103]	_	_
15-27	2018-2026	solution	object[102]|substance[103]	new[102]|giv[103]	_	_
15-28	2027-2028	.	_	_	_	_

#Text=The diffusion rate depends on many factors , such as the size of the molecules and pores , and the initial concentration of the aging solution .
16-1	2029-2032	The	abstract[105]	new[105]	_	_
16-2	2033-2042	diffusion	abstract|abstract[105]	giv|new[105]	coref	20-3
16-3	2043-2047	rate	abstract[105]	new[105]	_	_
16-4	2048-2055	depends	_	_	_	_
16-5	2056-2058	on	_	_	_	_
16-6	2059-2063	many	abstract[106]	giv[106]	_	_
16-7	2064-2071	factors	abstract[106]	giv[106]	_	_
16-8	2072-2073	,	abstract[106]	giv[106]	_	_
16-9	2074-2078	such	abstract[106]	giv[106]	_	_
16-10	2079-2081	as	abstract[106]	giv[106]	_	_
16-11	2082-2085	the	abstract[106]|abstract[107]	giv[106]|new[107]	ana	17-1[0_107]
16-12	2086-2090	size	abstract[106]|abstract[107]	giv[106]|new[107]	_	_
16-13	2091-2093	of	abstract[106]|abstract[107]	giv[106]|new[107]	_	_
16-14	2094-2097	the	abstract[106]|abstract[107]|object[108]	giv[106]|new[107]|new[108]	_	_
16-15	2098-2107	molecules	abstract[106]|abstract[107]|object[108]	giv[106]|new[107]|new[108]	_	_
16-16	2108-2111	and	abstract[106]|abstract[107]	giv[106]|new[107]	_	_
16-17	2112-2117	pores	abstract[106]|abstract[107]|object	giv[106]|new[107]|giv	_	_
16-18	2118-2119	,	abstract[106]	giv[106]	_	_
16-19	2120-2123	and	abstract[106]	giv[106]	_	_
16-20	2124-2127	the	abstract[106]|quantity[110]	giv[106]|new[110]	_	_
16-21	2128-2135	initial	abstract[106]|quantity[110]	giv[106]|new[110]	_	_
16-22	2136-2149	concentration	abstract[106]|quantity[110]	giv[106]|new[110]	_	_
16-23	2150-2152	of	abstract[106]|quantity[110]	giv[106]|new[110]	_	_
16-24	2153-2156	the	abstract[106]|quantity[110]|substance[111]	giv[106]|new[110]|giv[111]	_	_
16-25	2157-2162	aging	abstract[106]|quantity[110]|substance[111]	giv[106]|new[110]|giv[111]	_	_
16-26	2163-2171	solution	abstract[106]|quantity[110]|substance[111]	giv[106]|new[110]|giv[111]	_	_
16-27	2172-2173	.	_	_	_	_

#Text=It must be emphasized that the role of ethanol was simply to dissolve the drug and allow it to diffuse into the alcogel .
17-1	2174-2176	It	abstract	giv	ana	17-18
17-2	2177-2181	must	_	_	_	_
17-3	2182-2184	be	_	_	_	_
17-4	2185-2195	emphasized	_	_	_	_
17-5	2196-2200	that	_	_	_	_
17-6	2201-2204	the	abstract[113]	new[113]	coref	20-6[132_113]
17-7	2205-2209	role	abstract[113]	new[113]	_	_
17-8	2210-2212	of	abstract[113]	new[113]	_	_
17-9	2213-2220	ethanol	abstract[113]|substance	new[113]|new	coref	23-17
17-10	2221-2224	was	_	_	_	_
17-11	2225-2231	simply	_	_	_	_
17-12	2232-2234	to	_	_	_	_
17-13	2235-2243	dissolve	_	_	_	_
17-14	2244-2247	the	substance[115]	giv[115]	coref	18-8[0_115]
17-15	2248-2252	drug	substance[115]	giv[115]	_	_
17-16	2253-2256	and	_	_	_	_
17-17	2257-2262	allow	_	_	_	_
17-18	2263-2265	it	abstract	giv	_	_
17-19	2266-2268	to	_	_	_	_
17-20	2269-2276	diffuse	_	_	_	_
17-21	2277-2281	into	_	_	_	_
17-22	2282-2285	the	substance[117]	giv[117]	coref	21-25[145_117]
17-23	2286-2293	alcogel	substance[117]	giv[117]	_	_
17-24	2294-2295	.	_	_	_	_

#Text=Most research focuses only on the total drug loading content , but ignores the drug distribution and load mode in the carrier .
18-1	2296-2300	Most	abstract[118]	new[118]	_	_
18-2	2301-2309	research	abstract[118]	new[118]	_	_
18-3	2310-2317	focuses	_	_	_	_
18-4	2318-2322	only	_	_	_	_
18-5	2323-2325	on	_	_	_	_
18-6	2326-2329	the	abstract[121]	new[121]	_	_
18-7	2330-2335	total	abstract[121]	new[121]	_	_
18-8	2336-2340	drug	substance|abstract[121]	giv|new[121]	coref	18-15
18-9	2341-2348	loading	quantity|abstract[121]	giv|new[121]	coref	24-21
18-10	2349-2356	content	abstract[121]	new[121]	_	_
18-11	2357-2358	,	_	_	_	_
18-12	2359-2362	but	_	_	_	_
18-13	2363-2370	ignores	_	_	_	_
18-14	2371-2374	the	abstract[123]	new[123]	coref	21-19[143_123]
18-15	2375-2379	drug	substance|abstract[123]	giv|new[123]	coref	21-22[144_0]
18-16	2380-2392	distribution	abstract[123]	new[123]	_	_
18-17	2393-2396	and	_	_	_	_
18-18	2397-2401	load	_	_	_	_
18-19	2402-2406	mode	abstract	new	coref	24-20[171_0]
18-20	2407-2409	in	_	_	_	_
18-21	2410-2413	the	place[125]	new[125]	_	_
18-22	2414-2421	carrier	place[125]	new[125]	_	_
18-23	2422-2423	.	_	_	_	_

#Text=Moreover , drug-loading behaviors are commonly studied using adsorption isotherms and adsorption kinetic equations .
19-1	2424-2432	Moreover	_	_	_	_
19-2	2433-2434	,	_	_	_	_
19-3	2435-2447	drug-loading	abstract[126]	new[126]	_	_
19-4	2448-2457	behaviors	abstract[126]	new[126]	_	_
19-5	2458-2461	are	_	_	_	_
19-6	2462-2470	commonly	_	_	_	_
19-7	2471-2478	studied	_	_	_	_
19-8	2479-2484	using	_	_	_	_
19-9	2485-2495	adsorption	abstract|abstract[128]	new|new[128]	coref|coref	19-12|19-12
19-10	2496-2505	isotherms	abstract[128]	new[128]	_	_
19-11	2506-2509	and	_	_	_	_
19-12	2510-2520	adsorption	substance|abstract[130]	giv|new[130]	_	_
19-13	2521-2528	kinetic	abstract[130]	new[130]	_	_
19-14	2529-2538	equations	abstract[130]	new[130]	_	_
19-15	2539-2540	.	_	_	_	_

#Text=However , diffusion also play an important role in the drug-loading process , and we should consider both the effects of diffusion and adsorption/desorption .
20-1	2541-2548	However	_	_	_	_
20-2	2549-2550	,	_	_	_	_
20-3	2551-2560	diffusion	abstract	giv	coref	20-22
20-4	2561-2565	also	_	_	_	_
20-5	2566-2570	play	_	_	_	_
20-6	2571-2573	an	abstract[132]	giv[132]	_	_
20-7	2574-2583	important	abstract[132]	giv[132]	_	_
20-8	2584-2588	role	abstract[132]	giv[132]	_	_
20-9	2589-2591	in	abstract[132]	giv[132]	_	_
20-10	2592-2595	the	abstract[132]|abstract[134]	giv[132]|giv[134]	coref	23-19[161_134]
20-11	2596-2608	drug-loading	abstract[132]|substance|abstract[134]	giv[132]|new|giv[134]	coref	26-8
20-12	2609-2616	process	abstract[132]|abstract[134]	giv[132]|giv[134]	_	_
20-13	2617-2618	,	_	_	_	_
20-14	2619-2622	and	_	_	_	_
20-15	2623-2625	we	person	giv	ana	21-11
20-16	2626-2632	should	_	_	_	_
20-17	2633-2641	consider	_	_	_	_
20-18	2642-2646	both	abstract[136]	new[136]	_	_
20-19	2647-2650	the	abstract[136]	new[136]	_	_
20-20	2651-2658	effects	abstract[136]	new[136]	_	_
20-21	2659-2661	of	abstract[136]	new[136]	_	_
20-22	2662-2671	diffusion	abstract[136]|abstract	new[136]|giv	coref	21-31
20-23	2672-2675	and	abstract[136]	new[136]	_	_
20-24	2676-2697	adsorption/desorption	abstract[136]|abstract	new[136]|new	coref	21-33
20-25	2698-2699	.	_	_	_	_

#Text=So in this work , based on previous study , we have established a fundamental model to study the distribution of a drug in the alcogel and the interaction of diffusion and adsorption/desorption .
21-1	2700-2702	So	_	_	_	_
21-2	2703-2705	in	_	_	_	_
21-3	2706-2710	this	abstract[139]	giv[139]	_	_
21-4	2711-2715	work	abstract[139]	giv[139]	_	_
21-5	2716-2717	,	_	_	_	_
21-6	2718-2723	based	_	_	_	_
21-7	2724-2726	on	_	_	_	_
21-8	2727-2735	previous	abstract[140]	new[140]	_	_
21-9	2736-2741	study	abstract[140]	new[140]	_	_
21-10	2742-2743	,	_	_	_	_
21-11	2744-2746	we	person	giv	ana	23-3
21-12	2747-2751	have	_	_	_	_
21-13	2752-2763	established	_	_	_	_
21-14	2764-2765	a	abstract[142]	new[142]	_	_
21-15	2766-2777	fundamental	abstract[142]	new[142]	_	_
21-16	2778-2783	model	abstract[142]	new[142]	_	_
21-17	2784-2786	to	_	_	_	_
21-18	2787-2792	study	_	_	_	_
21-19	2793-2796	the	abstract[143]	giv[143]	_	_
21-20	2797-2809	distribution	abstract[143]	giv[143]	_	_
21-21	2810-2812	of	abstract[143]	giv[143]	_	_
21-22	2813-2814	a	abstract[143]|substance[144]	giv[143]|giv[144]	coref	24-24[172_144]
21-23	2815-2819	drug	abstract[143]|substance[144]	giv[143]|giv[144]	_	_
21-24	2820-2822	in	abstract[143]|substance[144]	giv[143]|giv[144]	_	_
21-25	2823-2826	the	abstract[143]|substance[144]|place[145]	giv[143]|giv[144]|giv[145]	_	_
21-26	2827-2834	alcogel	abstract[143]|substance[144]|place[145]	giv[143]|giv[144]|giv[145]	_	_
21-27	2835-2838	and	_	_	_	_
21-28	2839-2842	the	abstract[146]	new[146]	_	_
21-29	2843-2854	interaction	abstract[146]	new[146]	_	_
21-30	2855-2857	of	abstract[146]	new[146]	_	_
21-31	2858-2867	diffusion	abstract[146]|abstract	new[146]|giv	coref	25-18
21-32	2868-2871	and	abstract[146]	new[146]	_	_
21-33	2872-2893	adsorption/desorption	abstract[146]|abstract	new[146]|giv	_	_
21-34	2894-2895	.	_	_	_	_

#Text=In this paper , RSV-loaded silica aerogel ( RLSA ) was prepared by freeze-drying .
22-1	2896-2898	In	_	_	_	_
22-2	2899-2903	this	abstract[149]	giv[149]	_	_
22-3	2904-2909	paper	abstract[149]	giv[149]	_	_
22-4	2910-2911	,	_	_	_	_
22-5	2912-2922	RSV-loaded	substance[151]	giv[151]	coref	24-12[167_151]
22-6	2923-2929	silica	organization|substance[151]	giv|giv[151]	coref	24-12
22-7	2930-2937	aerogel	substance[151]	giv[151]	_	_
22-8	2938-2939	(	_	_	_	_
22-9	2940-2944	RLSA	object	new	coref	24-15
22-10	2945-2946	)	_	_	_	_
22-11	2947-2950	was	_	_	_	_
22-12	2951-2959	prepared	_	_	_	_
22-13	2960-2962	by	_	_	_	_
22-14	2963-2976	freeze-drying	abstract	new	_	_
22-15	2977-2978	.	_	_	_	_

#Text=The reason we used freeze drying instead of supercritical drying is that the RSV will lose ethanol during the slow replacement process in supercritical drying .
23-1	2979-2982	The	abstract[154]	new[154]	_	_
23-2	2983-2989	reason	abstract[154]	new[154]	_	_
23-3	2990-2992	we	person	giv	ana	34-1
23-4	2993-2997	used	_	_	_	_
23-5	2998-3004	freeze	_	_	_	_
23-6	3005-3011	drying	abstract	new	coref	23-9[157_0]
23-7	3012-3019	instead	_	_	_	_
23-8	3020-3022	of	_	_	_	_
23-9	3023-3036	supercritical	abstract[157]	giv[157]	coref	23-24[162_157]
23-10	3037-3043	drying	abstract[157]	giv[157]	_	_
23-11	3044-3046	is	_	_	_	_
23-12	3047-3051	that	_	_	_	_
23-13	3052-3055	the	substance[158]	giv[158]	coref	38-4[0_158]
23-14	3056-3059	RSV	substance[158]	giv[158]	_	_
23-15	3060-3064	will	_	_	_	_
23-16	3065-3069	lose	_	_	_	_
23-17	3070-3077	ethanol	substance	giv	coref	43-15
23-18	3078-3084	during	_	_	_	_
23-19	3085-3088	the	abstract[161]	giv[161]	_	_
23-20	3089-3093	slow	abstract[161]	giv[161]	_	_
23-21	3094-3105	replacement	abstract|abstract[161]	new|giv[161]	_	_
23-22	3106-3113	process	abstract[161]	giv[161]	_	_
23-23	3114-3116	in	abstract[161]	giv[161]	_	_
23-24	3117-3130	supercritical	abstract[161]|abstract[162]	giv[161]|giv[162]	coref	36-7[236_162]
23-25	3131-3137	drying	abstract[161]|abstract[162]	giv[161]|giv[162]	_	_
23-26	3138-3139	.	_	_	_	_

#Text=A series of characterizations were carried to compare the differences of silica aerogel and RLSA , and better understand the loading mode of the drug in silica aerogel .
24-1	3140-3141	A	abstract[163]	new[163]	_	_
24-2	3142-3148	series	abstract[163]	new[163]	_	_
24-3	3149-3151	of	abstract[163]	new[163]	_	_
24-4	3152-3169	characterizations	abstract[163]|abstract	new[163]|new	_	_
24-5	3170-3174	were	_	_	_	_
24-6	3175-3182	carried	_	_	_	_
24-7	3183-3185	to	_	_	_	_
24-8	3186-3193	compare	_	_	_	_
24-9	3194-3197	the	abstract[165]	new[165]	_	_
24-10	3198-3209	differences	abstract[165]	new[165]	_	_
24-11	3210-3212	of	abstract[165]	new[165]	_	_
24-12	3213-3219	silica	abstract[165]|organization|substance[167]|substance[168]	new[165]|giv|giv[167]|giv[168]	coref|coref|coref|coref|coref|coref|coref|coref|coref	24-27|24-27[174_167]|32-6[209_168]|24-27|24-27[174_167]|32-6[209_168]|24-27|24-27[174_167]|32-6[209_168]
24-13	3220-3227	aerogel	abstract[165]|substance[167]|substance[168]	new[165]|giv[167]|giv[168]	_	_
24-14	3228-3231	and	abstract[165]|substance[168]	new[165]|giv[168]	_	_
24-15	3232-3236	RLSA	abstract[165]|substance[168]|substance	new[165]|giv[168]|giv	coref	30-13
24-16	3237-3238	,	_	_	_	_
24-17	3239-3242	and	_	_	_	_
24-18	3243-3249	better	_	_	_	_
24-19	3250-3260	understand	_	_	_	_
24-20	3261-3264	the	abstract[171]	giv[171]	_	_
24-21	3265-3272	loading	quantity|abstract[171]	giv|giv[171]	_	_
24-22	3273-3277	mode	abstract[171]	giv[171]	_	_
24-23	3278-3280	of	abstract[171]	giv[171]	_	_
24-24	3281-3284	the	abstract[171]|substance[172]	giv[171]|giv[172]	_	_
24-25	3285-3289	drug	abstract[171]|substance[172]	giv[171]|giv[172]	_	_
24-26	3290-3292	in	abstract[171]|substance[172]	giv[171]|giv[172]	_	_
24-27	3293-3299	silica	abstract[171]|substance[172]|organization|substance[174]	giv[171]|giv[172]|giv|giv[174]	coref|coref|coref|coref	30-4|30-4[199_174]|30-4|30-4[199_174]
24-28	3300-3307	aerogel	abstract[171]|substance[172]|substance[174]	giv[171]|giv[172]|giv[174]	_	_
24-29	3308-3309	.	_	_	_	_

#Text=Furthermore , by establishing different boundary conditions and using Fick ’s second law to fit the apparent diffusion coefficient ( the apparent diffusion coefficients are all marked as “ diffusion coefficient ” in the manuscript hereafter for simplicity ) , three kinds of diffusion processes were studied .
25-1	3310-3321	Furthermore	_	_	_	_
25-2	3322-3323	,	_	_	_	_
25-3	3324-3326	by	_	_	_	_
25-4	3327-3339	establishing	_	_	_	_
25-5	3340-3349	different	abstract[176]	new[176]	_	_
25-6	3350-3358	boundary	place|abstract[176]	new|new[176]	_	_
25-7	3359-3369	conditions	abstract[176]	new[176]	_	_
25-8	3370-3373	and	_	_	_	_
25-9	3374-3379	using	_	_	_	_
25-10	3380-3384	Fick	person[177]|abstract[178]	new[177]|new[178]	_	_
25-11	3385-3387	’s	person[177]|abstract[178]	new[177]|new[178]	_	_
25-12	3388-3394	second	abstract[178]	new[178]	_	_
25-13	3395-3398	law	abstract[178]	new[178]	_	_
25-14	3399-3401	to	_	_	_	_
25-15	3402-3405	fit	_	_	_	_
25-16	3406-3409	the	abstract[180]	new[180]	_	_
25-17	3410-3418	apparent	abstract[180]	new[180]	_	_
25-18	3419-3428	diffusion	abstract|abstract[180]	giv|new[180]	coref	25-23
25-19	3429-3440	coefficient	abstract[180]	new[180]	_	_
25-20	3441-3442	(	_	_	_	_
25-21	3443-3446	the	abstract[182]	new[182]	_	_
25-22	3447-3455	apparent	abstract[182]	new[182]	_	_
25-23	3456-3465	diffusion	abstract|abstract[182]	giv|new[182]	coref	25-30
25-24	3466-3478	coefficients	abstract[182]	new[182]	_	_
25-25	3479-3482	are	_	_	_	_
25-26	3483-3486	all	_	_	_	_
25-27	3487-3493	marked	_	_	_	_
25-28	3494-3496	as	_	_	_	_
25-29	3497-3498	“	_	_	_	_
25-30	3499-3508	diffusion	abstract	giv	coref	25-44
25-31	3509-3520	coefficient	_	_	_	_
25-32	3521-3522	”	_	_	_	_
25-33	3523-3525	in	_	_	_	_
25-34	3526-3529	the	object[184]	new[184]	_	_
25-35	3530-3540	manuscript	object[184]	new[184]	_	_
25-36	3541-3550	hereafter	object[184]	new[184]	_	_
25-37	3551-3554	for	object[184]	new[184]	_	_
25-38	3555-3565	simplicity	object[184]|abstract	new[184]|new	ana	26-1
25-39	3566-3567	)	_	_	_	_
25-40	3568-3569	,	_	_	_	_
25-41	3570-3575	three	abstract[186]	new[186]	_	_
25-42	3576-3581	kinds	abstract[186]	new[186]	_	_
25-43	3582-3584	of	abstract[186]	new[186]	_	_
25-44	3585-3594	diffusion	abstract[186]|abstract|abstract[188]	new[186]|giv|new[188]	_	_
25-45	3595-3604	processes	abstract[186]|abstract[188]	new[186]|new[188]	_	_
25-46	3605-3609	were	_	_	_	_
25-47	3610-3617	studied	_	_	_	_
25-48	3618-3619	.	_	_	_	_

#Text=This facilitates the precise design of the drug-loading and -release system .
26-1	3620-3624	This	abstract	giv	_	_
26-2	3625-3636	facilitates	_	_	_	_
26-3	3637-3640	the	abstract[190]	new[190]	_	_
26-4	3641-3648	precise	abstract[190]	new[190]	_	_
26-5	3649-3655	design	abstract[190]	new[190]	_	_
26-6	3656-3658	of	abstract[190]	new[190]	_	_
26-7	3659-3662	the	abstract[190]|abstract[192]	new[190]|new[192]	_	_
26-8	3663-3675	drug-loading	abstract[190]|substance|abstract[192]	new[190]|giv|new[192]	_	_
26-9	3676-3679	and	abstract[190]|abstract[192]	new[190]|new[192]	_	_
26-10	3680-3688	-release	abstract[190]|abstract[192]	new[190]|new[192]	_	_
26-11	3689-3695	system	abstract[190]|abstract[192]	new[190]|new[192]	_	_
26-12	3696-3697	.	_	_	_	_

#Text=2 .
27-1	3698-3699	2	quantity	new	_	_
27-2	3700-3701	.	_	_	_	_

#Text=Results and Discussion
28-1	3702-3709	Results	abstract	new	_	_
28-2	3710-3713	and	_	_	_	_
28-3	3714-3724	Discussion	abstract	new	_	_

#Text=2.1 .
29-1	3725-3728	2.1	abstract	new	_	_
29-2	3729-3730	.	_	_	_	_

#Text=The Characterization of Silica Aerogel and Trans-Resveratrol ( RSV)-Loaded Silica Aerogel ( RLSA )
30-1	3731-3734	The	abstract[197]	new[197]	_	_
30-2	3735-3751	Characterization	abstract[197]	new[197]	_	_
30-3	3752-3754	of	abstract[197]	new[197]	_	_
30-4	3755-3761	Silica	abstract[197]|organization|substance[199]	new[197]|giv|giv[199]	coref|coref|coref|coref	30-10|30-9[203_199]|30-10|30-9[203_199]
30-5	3762-3769	Aerogel	abstract[197]|substance[199]	new[197]|giv[199]	_	_
30-6	3770-3773	and	abstract[197]	new[197]	_	_
30-7	3774-3791	Trans-Resveratrol	abstract[197]|substance	new[197]|giv	_	_
30-8	3792-3793	(	abstract[197]	new[197]	_	_
30-9	3794-3805	RSV)-Loaded	abstract[197]|person|substance[203]	new[197]|new|giv[203]	_	_
30-10	3806-3812	Silica	abstract[197]|organization|substance[203]	new[197]|giv|giv[203]	coref	32-6
30-11	3813-3820	Aerogel	abstract[197]|substance[203]	new[197]|giv[203]	_	_
30-12	3821-3822	(	_	_	_	_
30-13	3823-3827	RLSA	abstract	giv	coref	32-9
30-14	3828-3829	)	_	_	_	_

#Text=Figure 1
31-1	3830-3836	Figure	object[205]	new[205]	coref	39-1[252_205]
31-2	3837-3838	1	object[205]	new[205]	_	_

#Text=a shows the appearance of silica aerogel and RLSA after freeze drying .
32-1	3839-3840	a	_	_	_	_
32-2	3841-3846	shows	_	_	_	_
32-3	3847-3850	the	abstract[206]	new[206]	_	_
32-4	3851-3861	appearance	abstract[206]	new[206]	_	_
32-5	3862-3864	of	abstract[206]	new[206]	_	_
32-6	3865-3871	silica	abstract[206]|organization|substance[208]|substance[209]	new[206]|giv|new[208]|giv[209]	coref|coref|coref|coref|coref|coref	34-13|34-13[217_208]|34-13|34-13[217_208]|34-13|34-13[217_208]
32-7	3872-3879	aerogel	abstract[206]|substance[208]|substance[209]	new[206]|new[208]|giv[209]	_	_
32-8	3880-3883	and	abstract[206]|substance[209]	new[206]|giv[209]	_	_
32-9	3884-3888	RLSA	abstract[206]|substance[209]|object	new[206]|giv[209]|giv	coref	34-8[215_0]
32-10	3889-3894	after	_	_	_	_
32-11	3895-3901	freeze	_	_	_	_
32-12	3902-3908	drying	_	_	_	_
32-13	3909-3910	.	_	_	_	_

#Text=The mass of both is 200 mg .
33-1	3911-3914	The	quantity[211]	new[211]	_	_
33-2	3915-3919	mass	quantity[211]	new[211]	_	_
33-3	3920-3922	of	quantity[211]	new[211]	_	_
33-4	3923-3927	both	quantity[211]	new[211]	_	_
33-5	3928-3930	is	_	_	_	_
33-6	3931-3934	200	quantity[212]	new[212]	_	_
33-7	3935-3937	mg	quantity[212]	new[212]	_	_
33-8	3938-3939	.	_	_	_	_

#Text=We can see that the volume of the RLSA is larger than silica aerogel , and the color becomes more opaque .
34-1	3940-3942	We	person	giv	_	_
34-2	3943-3946	can	_	_	_	_
34-3	3947-3950	see	_	_	_	_
34-4	3951-3955	that	_	_	_	_
34-5	3956-3959	the	abstract[214]	new[214]	_	_
34-6	3960-3966	volume	abstract[214]	new[214]	_	_
34-7	3967-3969	of	abstract[214]	new[214]	_	_
34-8	3970-3973	the	abstract[214]|object[215]	new[214]|giv[215]	_	_
34-9	3974-3978	RLSA	abstract[214]|object[215]	new[214]|giv[215]	_	_
34-10	3979-3981	is	_	_	_	_
34-11	3982-3988	larger	_	_	_	_
34-12	3989-3993	than	_	_	_	_
34-13	3994-4000	silica	organization|substance[217]	giv|giv[217]	coref|coref|coref|coref	35-10|35-10[225_217]|35-10|35-10[225_217]
34-14	4001-4008	aerogel	substance[217]	giv[217]	_	_
34-15	4009-4010	,	_	_	_	_
34-16	4011-4014	and	_	_	_	_
34-17	4015-4018	the	abstract[218]	new[218]	_	_
34-18	4019-4024	color	abstract[218]	new[218]	_	_
34-19	4025-4032	becomes	_	_	_	_
34-20	4033-4037	more	_	_	_	_
34-21	4038-4044	opaque	_	_	_	_
34-22	4045-4046	.	_	_	_	_

#Text=A transmission electron microscope ( TEM ) image of silica aerogel shows that it is a dense structure formed by the accumulation of spherical particles , which is consistent with a scanning electron microscope ( SEM ) image .
35-1	4047-4048	A	object[221]	new[221]	coref	35-31[231_221]
35-2	4049-4061	transmission	organization|object[221]	new|new[221]	_	_
35-3	4062-4070	electron	substance|object[221]	new|new[221]	coref	35-33
35-4	4071-4081	microscope	object[221]	new[221]	_	_
35-5	4082-4083	(	_	_	_	_
35-6	4084-4087	TEM	abstract	new	_	_
35-7	4088-4089	)	_	_	_	_
35-8	4090-4095	image	abstract[223]	new[223]	ana	35-14[0_223]
35-9	4096-4098	of	abstract[223]	new[223]	_	_
35-10	4099-4105	silica	abstract[223]|organization|substance[225]	new[223]|giv|giv[225]	coref|coref|coref|coref	36-4|36-3[235_225]|36-4|36-3[235_225]
35-11	4106-4113	aerogel	abstract[223]|substance[225]	new[223]|giv[225]	_	_
35-12	4114-4119	shows	_	_	_	_
35-13	4120-4124	that	_	_	_	_
35-14	4125-4127	it	abstract	giv	coref	35-16[227_0]
35-15	4128-4130	is	_	_	_	_
35-16	4131-4132	a	abstract[227]	giv[227]	coref	35-38[0_227]
35-17	4133-4138	dense	abstract[227]	giv[227]	_	_
35-18	4139-4148	structure	abstract[227]	giv[227]	_	_
35-19	4149-4155	formed	_	_	_	_
35-20	4156-4158	by	_	_	_	_
35-21	4159-4162	the	abstract[228]	new[228]	_	_
35-22	4163-4175	accumulation	abstract[228]	new[228]	_	_
35-23	4176-4178	of	abstract[228]	new[228]	_	_
35-24	4179-4188	spherical	abstract[228]|object[229]	new[228]|new[229]	_	_
35-25	4189-4198	particles	abstract[228]|object[229]	new[228]|new[229]	_	_
35-26	4199-4200	,	_	_	_	_
35-27	4201-4206	which	_	_	_	_
35-28	4207-4209	is	_	_	_	_
35-29	4210-4220	consistent	_	_	_	_
35-30	4221-4225	with	_	_	_	_
35-31	4226-4227	a	object[231]	giv[231]	appos	35-36[0_231]
35-32	4228-4236	scanning	object[231]	giv[231]	_	_
35-33	4237-4245	electron	substance|object[231]	giv|giv[231]	_	_
35-34	4246-4256	microscope	object[231]	giv[231]	_	_
35-35	4257-4258	(	_	_	_	_
35-36	4259-4262	SEM	object	giv	_	_
35-37	4263-4264	)	_	_	_	_
35-38	4265-4270	image	abstract	giv	coref	36-10[239_0]
35-39	4271-4272	.	_	_	_	_

#Text=Compared with the silica aerogel after supercritical drying , its skeleton structure is denser and the density is larger .
36-1	4273-4281	Compared	_	_	_	_
36-2	4282-4286	with	_	_	_	_
36-3	4287-4290	the	substance[235]	giv[235]	ana	36-10[0_235]
36-4	4291-4297	silica	organization|substance[235]	giv|giv[235]	coref	42-19
36-5	4298-4305	aerogel	substance[235]	giv[235]	_	_
36-6	4306-4311	after	_	_	_	_
36-7	4312-4325	supercritical	abstract[236]	giv[236]	coref	45-2[277_236]
36-8	4326-4332	drying	abstract[236]	giv[236]	_	_
36-9	4333-4334	,	_	_	_	_
36-10	4335-4338	its	substance|abstract[239]	giv|giv[239]	_	_
36-11	4339-4347	skeleton	person|abstract[239]	new|giv[239]	coref	42-17[262_0]
36-12	4348-4357	structure	abstract[239]	giv[239]	_	_
36-13	4358-4360	is	_	_	_	_
36-14	4361-4367	denser	_	_	_	_
36-15	4368-4371	and	_	_	_	_
36-16	4372-4375	the	quantity[240]	new[240]	_	_
36-17	4376-4383	density	quantity[240]	new[240]	_	_
36-18	4384-4386	is	_	_	_	_
36-19	4387-4393	larger	_	_	_	_
36-20	4394-4395	.	_	_	_	_

#Text=However , the pore size is smaller and most of it consists of micropores .
37-1	4396-4403	However	_	_	_	_
37-2	4404-4405	,	_	_	_	_
37-3	4406-4409	the	abstract[242]	new[242]	ana	37-11[0_242]
37-4	4410-4414	pore	abstract|abstract[242]	new|new[242]	coref	43-22[268_0]
37-5	4415-4419	size	abstract[242]	new[242]	_	_
37-6	4420-4422	is	_	_	_	_
37-7	4423-4430	smaller	_	_	_	_
37-8	4431-4434	and	_	_	_	_
37-9	4435-4439	most	_	_	_	_
37-10	4440-4442	of	_	_	_	_
37-11	4443-4445	it	abstract	giv	coref	38-11[249_0]
37-12	4446-4454	consists	_	_	_	_
37-13	4455-4457	of	_	_	_	_
37-14	4458-4468	micropores	object	new	_	_
37-15	4469-4470	.	_	_	_	_

#Text=The structure of RSV has a long rod shape with the size on the order of micrometers shown in
38-1	4471-4474	The	abstract[245]	new[245]	_	_
38-2	4475-4484	structure	abstract[245]	new[245]	_	_
38-3	4485-4487	of	abstract[245]	new[245]	_	_
38-4	4488-4491	RSV	abstract[245]|abstract	new[245]|giv	coref	42-5[257_0]
38-5	4492-4495	has	_	_	_	_
38-6	4496-4497	a	abstract[248]	new[248]	coref	42-9[259_248]
38-7	4498-4502	long	abstract[248]	new[248]	_	_
38-8	4503-4506	rod	object|abstract[248]	new|new[248]	coref	42-12
38-9	4507-4512	shape	abstract[248]	new[248]	_	_
38-10	4513-4517	with	abstract[248]	new[248]	_	_
38-11	4518-4521	the	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
38-12	4522-4526	size	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
38-13	4527-4529	on	abstract[248]|abstract[249]	new[248]|giv[249]	_	_
38-14	4530-4533	the	abstract[248]|abstract[249]|abstract[250]	new[248]|giv[249]|new[250]	ana	40-2[0_250]
38-15	4534-4539	order	abstract[248]|abstract[249]|abstract[250]	new[248]|giv[249]|new[250]	_	_
38-16	4540-4542	of	abstract[248]|abstract[249]|abstract[250]	new[248]|giv[249]|new[250]	_	_
38-17	4543-4554	micrometers	abstract[248]|abstract[249]|abstract[250]|abstract	new[248]|giv[249]|new[250]|new	_	_
38-18	4555-4560	shown	_	_	_	_
38-19	4561-4563	in	_	_	_	_

#Text=Figure 1
39-1	4564-4570	Figure	object[252]	giv[252]	coref	41-1[254_252]
39-2	4571-4572	1	object[252]	giv[252]	_	_

#Text=e. It can be seen from
40-1	4573-4575	e.	_	_	_	_
40-2	4576-4578	It	abstract	giv	_	_
40-3	4579-4582	can	_	_	_	_
40-4	4583-4585	be	_	_	_	_
40-5	4586-4590	seen	_	_	_	_
40-6	4591-4595	from	_	_	_	_

#Text=Figure 1
41-1	4596-4602	Figure	object[254]	giv[254]	_	_
41-2	4603-4604	1	object[254]	giv[254]	_	_

#Text=c , f that the recrystallized RSV with a micron-sized long rod shape is integrated with the dense silica network skeleton .
42-1	4605-4606	c	abstract	new	appos	42-3[256_0]
42-2	4607-4608	,	_	_	_	_
42-3	4609-4610	f	abstract[256]	giv[256]	ana	43-1[0_256]
42-4	4611-4615	that	abstract[256]	giv[256]	_	_
42-5	4616-4619	the	abstract[256]|abstract[257]	giv[256]|giv[257]	coref	43-7[264_257]
42-6	4620-4634	recrystallized	abstract[256]|abstract[257]	giv[256]|giv[257]	_	_
42-7	4635-4638	RSV	abstract[256]|abstract[257]	giv[256]|giv[257]	_	_
42-8	4639-4643	with	abstract[256]|abstract[257]	giv[256]|giv[257]	_	_
42-9	4644-4645	a	abstract[256]|abstract[257]|abstract[259]	giv[256]|giv[257]|giv[259]	_	_
42-10	4646-4658	micron-sized	abstract[256]|abstract[257]|abstract[259]	giv[256]|giv[257]|giv[259]	_	_
42-11	4659-4663	long	abstract[256]|abstract[257]|abstract[259]	giv[256]|giv[257]|giv[259]	_	_
42-12	4664-4667	rod	abstract[256]|abstract[257]|object|abstract[259]	giv[256]|giv[257]|giv|giv[259]	_	_
42-13	4668-4673	shape	abstract[256]|abstract[257]|abstract[259]	giv[256]|giv[257]|giv[259]	_	_
42-14	4674-4676	is	abstract[256]	giv[256]	_	_
42-15	4677-4687	integrated	abstract[256]	giv[256]	_	_
42-16	4688-4692	with	_	_	_	_
42-17	4693-4696	the	person[262]	giv[262]	_	_
42-18	4697-4702	dense	person[262]	giv[262]	_	_
42-19	4703-4709	silica	object|person[262]	giv|giv[262]	coref	43-25
42-20	4710-4717	network	place|person[262]	new|giv[262]	_	_
42-21	4718-4726	skeleton	person[262]	giv[262]	_	_
42-22	4727-4728	.	_	_	_	_

#Text=This is may be due to the RSV dissolving into small molecules in an ethanol solution , which can diffuse into the pores of silica alcogel .
43-1	4729-4733	This	abstract	giv	_	_
43-2	4734-4736	is	_	_	_	_
43-3	4737-4740	may	_	_	_	_
43-4	4741-4743	be	_	_	_	_
43-5	4744-4747	due	_	_	_	_
43-6	4748-4750	to	_	_	_	_
43-7	4751-4754	the	abstract[264]	giv[264]	coref	44-3[0_264]
43-8	4755-4758	RSV	abstract[264]	giv[264]	_	_
43-9	4759-4769	dissolving	_	_	_	_
43-10	4770-4774	into	_	_	_	_
43-11	4775-4780	small	substance[265]	new[265]	_	_
43-12	4781-4790	molecules	substance[265]	new[265]	_	_
43-13	4791-4793	in	substance[265]	new[265]	_	_
43-14	4794-4796	an	substance[265]|substance[267]	new[265]|new[267]	_	_
43-15	4797-4804	ethanol	substance[265]|substance|substance[267]	new[265]|giv|new[267]	_	_
43-16	4805-4813	solution	substance[265]|substance[267]	new[265]|new[267]	_	_
43-17	4814-4815	,	_	_	_	_
43-18	4816-4821	which	_	_	_	_
43-19	4822-4825	can	_	_	_	_
43-20	4826-4833	diffuse	_	_	_	_
43-21	4834-4838	into	_	_	_	_
43-22	4839-4842	the	abstract[268]	giv[268]	_	_
43-23	4843-4848	pores	abstract[268]	giv[268]	_	_
43-24	4849-4851	of	abstract[268]	giv[268]	_	_
43-25	4852-4858	silica	abstract[268]|organization|substance[270]	giv[268]|giv|new[270]	_	_
43-26	4859-4866	alcogel	abstract[268]|substance[270]	giv[268]|new[270]	_	_
43-27	4867-4868	.	_	_	_	_

#Text=However , RSV precipitates due to minimal solubility in water during solvent replacement .
44-1	4869-4876	However	_	_	_	_
44-2	4877-4878	,	_	_	_	_
44-3	4879-4882	RSV	substance	giv	coref	45-9[279_0]
44-4	4883-4895	precipitates	_	_	_	_
44-5	4896-4899	due	_	_	_	_
44-6	4900-4902	to	_	_	_	_
44-7	4903-4910	minimal	substance[272]	new[272]	_	_
44-8	4911-4921	solubility	substance[272]	new[272]	_	_
44-9	4922-4924	in	substance[272]	new[272]	_	_
44-10	4925-4930	water	substance[272]|substance	new[272]|new	_	_
44-11	4931-4937	during	_	_	_	_
44-12	4938-4945	solvent	substance|abstract[275]	new|new[275]	coref|coref	45-5[278_0]|45-5[278_0]
44-13	4946-4957	replacement	abstract[275]	new[275]	_	_
44-14	4958-4959	.	_	_	_	_

#Text=After freeze drying , the solvent evaporates and the RSV recrystallizes .
45-1	4960-4965	After	_	_	_	_
45-2	4966-4972	freeze	abstract|abstract[277]	new|giv[277]	_	_
45-3	4973-4979	drying	abstract[277]	giv[277]	_	_
45-4	4980-4981	,	_	_	_	_
45-5	4982-4985	the	substance[278]	giv[278]	_	_
45-6	4986-4993	solvent	substance[278]	giv[278]	_	_
45-7	4994-5004	evaporates	_	_	_	_
45-8	5005-5008	and	_	_	_	_
45-9	5009-5012	the	substance[279]	giv[279]	_	_
45-10	5013-5016	RSV	substance[279]	giv[279]	_	_
45-11	5017-5031	recrystallizes	_	_	_	_
45-12	5032-5033	.	_	_	_	_
